| Today's Big NewsMay 9, 2023 |
|
Choosing the best eCOA platform that considers the needs of patients, site staff and data requirements are all critical factors. But it takes more to reach success. Download your eCOA Technology Guide.
|
|
| By Nick Paul Taylor,Max Bayer Novavax is reducing its head count by 25%. After trying to cut costs without laying off staff, the vaccine company has now accepted it will need to part ways with hundreds of employees to align its spending with the dwindling size of the COVID-19 opportunity. |
|
|
|
By James Waldron Last month, Fierce Biotech told you about an unknown number of layoffs due to hit Takeda employees as the Japanese pharma moves away from early-stage R&D work in adeno-associated virus-based gene therapies and rare hematology. Now, we’ve got a better sense of the workforce impact. |
By Gabrielle Masson EQRx is abandoning its plan to provide drugs that are typically expensive at lower prices. The biotech is also cutting ties with two of its partners, letting go of 170 staff members and slashing all assets from its pipeline except one. |
Sponsored by ValGenesis Inc. Cell and gene therapies hold great promise but can also carry serious risks. Applying a risk-based approach during development and manufacturing increases patient safety and product quality. Read more. |
By Nick Paul Taylor Roche is stepping up the defense of its critical HER2 franchise, committing $70 million in upfront and near-term payments to secure global rights to Zion Pharma’s early-phase treatment of brain metastases. |
Sponsored by Precision for Medicine Discover Sofia Baig's vision for clinical research, data-driven insights & patient centricity at Precision for Medicine! |
By Eric Sagonowsky,Max Bayer,Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Andrea Park,Annalee Armstrong,Ben Adams,Gabrielle Masson,James Waldron,Nick Paul Taylor The times are changing in biopharma. We hope our selections for this year's Most Influential People in Biopharma special report reflect the trends many of our readers are seeing in the industry. |
By Annalee Armstrong Gilead has found a potential friend for breast cancer med Trodelvy in PARP1 and MK2 Inhibitor specialist XinThera, which will now come under the Big Pharma's wing. |
By Gabrielle Masson The FDA has lifted its partial clinical hold on Salarius Pharmaceuticals’ lead asset seclidemstat in a rare cancer indication, a hold that was put in place last fall after a patient death was reported. |
By James Waldron Biotech may be an inherently risky business, but ADC Therapeutics is now keen to pursue a low-risk R&D strategy that will see it focus on assets it deems most likely to make it to market. |
By Annalee Armstrong Enanta Pharmaceuticals’ COVID-19 drug reduced some symptoms of the respiratory disease but did not reduce viral load or time to improvement when compared to placebo. Executives pointed to a tighter analysis of key symptoms for signs that EDP-235 could have value on the market—so long as a partner helps them get there. |
By Max Bayer New research from Harvard scientists confirmed suspicions that the gut microbiome could be responsible for why checkpoint inhibitors aren't effective in some patients. |
By Helen Floersh A new universal receptor system designed by a research team from the University of Pittsburgh could make engineering custom T cell therapies far more efficient. |
By Andrea Park With the sell-off of its applied science, food and enterprise services businesses now complete, PerkinElmer is charting a new path with its remaining diagnostics and life sciences divisions. |
By Kevin Dunleavy Pfizer’s proposed $43 billion acquisition of Seagen two months ago was the largest deal in biopharma since 2019 but it came during a period when M&A activity has been limited. Analysts from EY and West Monroe however believe that the M&A market is about to grow because of a confluence of factors. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss how the healthcare industry is addressing its role in climate change. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ Our speaking faculty features leaders from big pharma, small-mid size pharma, biotechs, and more. Save $500 when you. Register Today!
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
